purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation ocgn earnings call period ending march image source motley fool ocugen ocgn q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning welcome ocugens business update certain financial year ending please note call recorded time participant line listenonly mode following speaker commentary questionandanswer session turn call tiffany hamilton ocugens head communication may begintiffany hamilton head corporate communication thank operator joining today ocugens chairman ceo cofounder dr shankar musunuri provide business update michael breininger corporate controller also call provide certain financials year ending finally dr huma qamar chief medical officer available answer question qa morning issued press release detailing business operational highlight year ending encourage listener review press release available website ocugencomthis call recorded replay accompanying slide presentation available investor section ocugen website approximately day presentation contains forwardlooking statement within meaning private security litigation reform act subject risk uncertainty may case use term predicts belief potential proposed continue estimate anticipates expects plan intends may could might word convey uncertainty future event outcome identify forwardlooking statement statement include limited statement regarding clinical development activity related anticipated timeline statement subject numerous important factor risk uncertainty may cause actual event result differ materially current expectation risk uncertainty fully described periodic filing security exchange commission sec including risk factor described section entitled risk factor quarterly annual report filed sec forwardlooking statement make presentation speak date presentation except required law assume obligation update forwardlooking statement contained presentation whether result new information future event otherwise date presentation finally annual report form k expected filed later april turn call dr musunuri shankar musunuri cofounder chairman chief executive officer thank tiffany good morning thank joining u today looking back team unwavering dedication set stage transformative modified gene therapy program blindness disease stride made science profoundly personal evidenced significant benefit therapy potentially offer patient allow briefly share inspiring account justifies core motto courageous innovation patient ocu phase trial retinitis pigmentosa rare genetic disorder degrades retinal cell affect approximately people yous million people worldwide yearold patient began experiencing onset rp disease progressed vision worsened increasingly threatened livelihood ability function independently joining trial faced future dominated visual impairment available treatment option trial proven lifealtering experience also family year following treatment ocu report gradual restoration sight treated eye matter fact shared dosed eye worse two better untreated eye getting know patient like hearing realworld story fortify resolve bold innovation deliver safe effective therapy significantly underserved disease reference also posted patient video patient section corporate website review milestone proud achieved recognition fda agency several area first touch upon vaccine cell therapy platform vaccine development front team diligent pursuit nondilutive funding avenue culminated collaboration niaid part nih include ocu project nextgen initiative test therapeutic potential several early stage vaccine candidate combating covid initiative commitment cover cost early stage vaccine candidate strategic leap forward allowing u address public health imperative minimal financial impact shareholder addition stateoftheart cgmp facility renovation completed last year paving way production neocart phase ready regenerative cell therapy platform acquiring asset predecessor presented u invaluable opportunity thoroughly evaluating compatibility ocugens existing pipeline rd expertise acknowledge responsibility future patient eagerly waiting awaiting cell therapy market poised reach around billion encouraging regulatory landscape strategically evaluating alternative ensure neocarts development stay track maximize value patient shareholder get modified gene therapy update would like take moment discus broader landscape gene therapy market ocugens position within believe gene therapy market cusp significant transformation current market economics indicate growing interest genetic cell therapy fueled technological advancement increased investment clinical activity supportive regulatory environment transaction within past year symbolized appeal need gene therapy industry analyst project global gene therapy market expected surpass billion end decade immense growth prediction driven unmet medical need growing pool million patient globally suffering disease recently untreatable last year achieved alignment fda design aspect ocu phase study prepare initiate pivotal ocu phase clinical trial would like emphasize gene therapy phase trial broad rp designation fda alignment phase trial design ocu rooted compelling positive preliminary safety efficacy result demonstrated phase trial last year multiluminescence mobility testing mlmt low luminescence visual acuity llva bestcorrected visual acuity bcba efficacy measurement patient receiving treatment category measurement result indicated improvement preservation eye treated ocu result affirm understanding geneagnostic mechanism action design proposed phase study rp patient fda included luminescencedependent navigation assessment ldna measure functional vision change patient inherited retinal disease primary endpoint upcoming multicenter randomized patient phase study feature two arm rho geneagnostic patient arm arm participant randomized treatment group untreated control group upon receiving approval fda anticipate initiating phase trial patient rp collaborative iterative conversation fda advance ocu phase affirm acute need therapy rp patient clinical data potential foster transformative impact onto ocu ocust current treatment landscape geographic atrophy ga stargardt disease extremely limited estimated million patient ga market yous saw momentum recent drug approval however treatment option significant limitation require multiple injection per year impacting patient compliance target one pathway contributing ga ocu regulates multiple pathway involved disease including lipid metabolism inflammation oxidative stress membrane attack complex complement potential provide onetime treatment life presently approved treatment people living stargardt disease orphan blindness disease affect approximately people yous alone first quarter completed dosing cohort ocu armada ocust gardian phase clinical trial data safety monitoring board ocust clinical trial determined safety tolerability profile ocust favorable approved proceed dosing medium dose ocust dose escalation phase study fda orphan drug designation ocust last year underscore commitment blindness condition require ongoing treatment high unmet medical need collaboration premier retinal surgery center across yous pivotal bolstering patient recruitment effort deepening understanding maturing pipeline clinical progress ocugen positioned forefront burgeoning gene therapy market fda rmat orphan drug designation granted gene therapy program demonstrate potential lead area based patient testimony ocu clinical trial making headway already making meaningful difference ultimate goal ocugen develop deliver safe effective therapy patient battling condition impact quality life functional independence february clinical showcase shared expected pathway market approval ocu help u navigate critical phase ensure deliver longterm strategy recently announced appointment dr huma qamar chief medical officer dr qamars extensive experience contribution date previous role head clinical development clinical operation pivotal team expertise foundational knowledge ocugens modified gene therapy platform instrumental success clinical program turn call michael breininger corporate controller provide financials mikemichael breininger corporate controller thank shankar press release morning noted restate consolidated financial statement year ended december connection filing form k similarly company include restated unaudited financial information first three quarter identified error restated period relate company noncash accounting estimated cost one collaboration arrangement however company expect error result impact cash position cash runway financial projection ocugens cash cash equivalent investment totaled million december compared million december expect current cash cash equivalent investment enable u fund operation fourth quarter fourth quarter turn call operator question question answer operatorthank floor open question operator instruction first question come line swayampakula ramakanth hc wainwright line openrk swayampakula hc wainwright company analyst thank good morning shankar ocu program know expect hear next clinical update also else need completed get phase program startedshankar musunuri cofounder chairman chief executive officer rk good morning let dr qamar answer question go aheadhuma qamar chief medical officer thank shankar thank question ocu phase study completed enrollment retinitis pigmentosa patient lca well periodically providing update come completed enrollment retinitis pigmentosa lca portion studyrk swayampakula hc wainwright company analyst okshankar musunuri cofounder chairman chief executive officer rk expecting u talking phase rk swayampakula hc wainwright company analyst yeah else need get done thathuma qamar chief medical officer ok phase actively working fda anticipating working closely fda grateful support fda alignment clinical protocol go well commencing study april monthrk swayampakula hc wainwright company analyst good regarding data safety monitoring board approving move next dose level st point many patient would entering next phase dose evaluation also would releasing data initial cohort would time enough data multiple cohortshuma qamar chief medical officer good question moving toward medium dose cohort phase portion study design dose escalation portion enrolling three patient well high dose cohort three well planning update periodically safety update preliminary safety update pretty soon dsmb go high dose cohort look toward dose escalation portion studyrk swayampakula hc wainwright company analyst thank much one last question neocart based comment look like ready term manufacturing part manufacturing product needed study else needed get started conversation potential collaborator looking know move conversation next levelshankar musunuri cofounder chairman chief executive officer great question yeah facility ready alignment fda move phase rmat designation everything set mean obviously phase twoyear study take recruitment time capital commitment needed exactly working potential partner make sure got funding lined continue clinical trial start need make sure adequate funding support finish itrk swayampakula hc wainwright company analyst good thank much taking questionsoperatorour next question come line daniil gataulin chardan capital market line opendaniil gataulin chardan capital market analyst hey good morning guy thank taking question congrats progress one phase ocu trial minimum number mutation need looking need include gain broad mutationagnostic labelhuma qamar chief medical officer take question answer excluding rhodopsin one arm geneagnostic arm patient patient rhodopsin arm geneagnostic approach active arm controldaniil gataulin chardan capital market analyst ok internally guiding many geneagnostic rp geneticagnostic patient looking differenthuma qamar chief medical officer exactly broader rp indication product addressing patient unmet medical need opening phase trial actually validate novel modified gene therapy platformdaniil gataulin chardan capital market analyst done right thank youoperatorthis concludes qa portion turn call back dr shankar musunurishankar musunuri cofounder chairman chief executive officer thank close today session want highlight journey strategy focus patient manifested numerous regulatory milestone advancement gene therapy pipeline ocu program cusp phase trial line bla approval target timeline completion first cohort dosing ocu st trial stand exciting juncture clinical progress potential gene therapy market dynamic growth strategic position within signal future ripe opportunity continue advance pipeline also continue pursue partnership opportunity ocu want thank stakeholder continued trust support entered year great momentum clear objective driven mission bring gamechanging gene cell therapy vaccine market working even harder provide access patient globally thanks everyone great dayoperatoroperator signoff duration minutescall participantstiffany hamilton head corporate communicationsshankar musunuri cofounder chairman chief executive officermichael breininger corporate controllerrk swayampakula hc wainwright company analysthuma qamar chief medical officerdaniil gataulin chardan capital market analyst ocgn analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy